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Abstract
Oncolytic adenoviruses are being tested as potential
therapies for human malignant tumors, including glio-
mas. Here we report for the first time that a mutation
in the E1A gene results in low levels of E1A protein,
conditioning the replication of mutant adenoviruses
specifically to cancer cells. In this study, we compared
the oncolytic potencies of three mutant adenoviruses
encompassing deletions within the CR1 (Delta-39),
CR2 (Delta-24) regions, or both regions (Delta-24/39)
of the E1A protein. Delta-39 and Delta-24 induced a
cytopathic effect with similar efficiency in glioma cells
and a comparable capacity for replication. Importantly,
the activity of Delta-39 was significantly attenuated
compared to Delta-24 in proliferating normal human
astrocytes. Direct analyses of the activation of E2F-1
promoter demonstrated the inability of Delta-39 to in-
duce S-phase–related transcriptional activity in normal
cells. Interestingly, E1A protein levels in cells infected
with Delta-39 were remarkably downmodulated. Fur-
thermore, protein stability studies revealed enhanced
degradation of CR1 mutant E1A proteins, and inhibi-
tion of the proteasome activity resulted in the strik-
ing rescue of E1A levels. We conclude that the level
of E1A protein is a critical determinant of oncolytic
phenotype and we propose a completely novel strat-
egy for the design and construction of conditionally
replicative adenoviruses.
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Introduction
Oncolytic adenoviruses, engineered to selectively replicate
in and lyse cancer cells, hold great potential as efficacious
therapeutic agents for primary brain tumors [1–4]. One of
the strategies commonly used to design oncolytic adeno-
viruses is to genetically modify E1A protein binding of key
cellular proteins. Comparing E1A protein sequences of
various adenovirus serotypes identified three evolution-
ary conserved regions (CR), pointing to their critical roles
in E1A activity [5]. Thus, the CR1 (42–72 aa) and CR2
(115–140 aa) regions in type 5 human adenovirus (Ad5) in-
clude E1A binding sites for p300/CBP, Rb, and Rb-related
proteins [5,6]. One critical consequence of their ensuing inter-
actions is disrupting pRb binding to E2F. This dysregulation
stimulates the transcription of E2F-responsive genes and in-
duces quiescent cells to enter the S-phase [7]. Interactions
between E1A and cell cycle modulators would be critical in
infected quiescent normal cells in which the G1 checkpoint
is tightly regulated by a network of proteins with overlap-
ping functions. The effect of such viral–cellular protein inter-
actions would, however, not be particularly critical in cancer
cells where G1/S transition controls are already partially in-
activated. This is the underlying rationale that is driving the
assessment of E1A mutant adenoviruses as preferentially or
exclusively acquiring lytic properties in cancer cells [1,2].
In this work, we compared the antiglioma efficacy and
replication selectivity of a CR1 mutant adenovirus (Delta-39)
with the CR2 mutant adenovirus, Delta-24 [3]. Importantly,
we uncover that cells infected with Delta-39 expressed low
levels of E1A protein due to protein instability and enhanced
proteosomal-mediated degradation. However, although the low
level of E1A did not substantially impair the ability of Delta-39
to replicate in cancer cells, the activity of Delta-39 was sig-
nificantly attenuated in proliferating normal cells. Delta-39 is
thus an excellent potential candidate for further development
as an antiglioma therapeutic tool. This is the first report show-
ing that the level of E1A protein is a critical determinant of
the selectivity of oncolytic adenoviruses and proposes a com-
pletely novel strategy for the design and construction of con-
ditionally replicative adenovirus.
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U-87 MG, D-54 MG, U-251 MG, and 293 cells were cul-
tured as previously described [3]. Normal human astrocytes
(NHA) were obtained from Clonetics/BioWhittaker (Wakers-
ville,MD) and cultured using themanufacturer’s specifications.
Adenoviruses
Delta-24 characteristics were reported previously [2]. The
39-nucleotide deletion, corresponding to48 to60aa in theCR1
region of the E1A protein, in pXC1 (Microbix Biosystems, Inc.,
Ontario, Canada) or pXC1-D24 [3]) was accomplished by
replacing the BamHI/XbaI fragment, encompassing the 701
to 739 nt region of the Ad5 genome,with two polymerase chain
reaction (PCR) fragments flanking this deleted region, result-
ing in pXC1-D39 (harboring a 701–739 nt deletion in the
adenoviral genome) and pXC1-D24/39 (harboring deletions
of 701–739 nt and 923–946 nt in the Ad5 genome). XC1-D39
or pXC1-D24/39 was cotransfected with pBHG10 (Microbix
Biosystems, Inc.) into 293 cells to generate the Delta-39 and
Delta-24/39 adenoviruses, respectively, and then amplified in
293 cells and purified by CsCl gradient centrifugation [8]. To
confirm the deletions, PCR amplification of a region of the Ad5
genome, which encompasses the 39- and 24-bp deletions in
the E1A region, was followed by XhoII or BstXI enzymatic
digestion. Controls include wild-type adenovirus (Adwt) [9],
ultraviolet-inactivated adenovirus, and mock infections [3].
Immunoprecipitation and Immunoblotting
Cells infected with Adwt, Delta-24 at 20 MOI, or Delta-24/
39 at 50 MOI, or mock-infected were collected 16 hours after
infection and suspended in ice-cold PBS plus 0.5%NP40 and
a protease inhibitor cocktail (Sigma, St. Louis, MO), and then
lysed by sonication. For each sample, 2 mg of anti-E1A
antibody and 20 ml of Protein A Agarose beads (Oncogene,
Cambridge, MA) were added to 400 mg of cell lysate proteins.
After 4 hours of immunoprecipitation at 4jC, the beads were
pelleted and washed. The precipitated proteins or cell lysate
proteins were dissolved in 1 SDS loading buffer, separated
by SDS-PAGE, and probed with antibodies against adeno-
virus 2 E1A (13 S-5), p300 (C-20), Rb (C-15)-G, or b-actin
(Santa Cruz Biotechnology, Santa Cruz, CA). For Western
blot experiments, cells were infected with 50 MOI of each
adenovirus; however, different viral dosages were used for
infection to achieve similar E1A expression levels in cell
lysates for immunoprecipitation.
Cell Viability and Viral Replication Assays
Crystal violet, MTT, and tissue culture infection dose50
(TCID50) assays were conducted as described previously
[3,10]. Final viral titers were determined as plaque-forming
units (pfu/ml) according to the validated method developed
by Quantum Biotechnology (Carlsbad, CA).
Luciferase Assay
A total of 3  104/well cells was seeded in 24-well plates
and grown for 24 hours. Each well was cotransfected with
250 ng of the E2F-1 reporter plasmid [11] and 1 ng of pRL-
CMV as control for transfection efficiency (Promega Life
Science, Madison, MI) with FuGENE 6 (Roche Molecular
Biochemicals, Indianapolis, IN). The cells were infected
2 hours later with 5 MOI of the adenoviruses. Twenty-four
hours after transfection, the cells were lysed and lucifer-
ase activity was assayed with a luminometer.
E1A Protein Stability Studies
A total of 6  104 cells/well was seeded in 24-well plates
and infected 24 hours later with adenoviruses at 50 MOI.
Sixteen hours later, 100 mM anisomycin (Sigma) was added
to the culture to inhibit protein synthesis. Cell lysates were
collected in 1 SDS loading buffer (100 ml/well). An equal
volume of cell lysates was used for immunoblotting analy-
sis of E1A protein expression.
Proteasomal-Mediated Degradation of E1A
Cells were infected with adenoviruses for 16 hours at
50 MOI and then either mock-treated or treated with 10 mM
lactacystin (Calbiochem, La Jolla, CA) for 24 hours. The cell
lysates were subjected to immunoblotting analysis.
Results
Construction and Characterization of Delta-39 and
Delta-24/39 Adenoviruses
The Delta-24 adenovirus harbors a 24-nucleotide de-
letion (from 923 to 946 nt in the Ad5 genome) correspond-
ing to 122 to 129 aa in the CR2 region of E1A protein, which
is responsible for pRb binding [3]. The Delta-39 adeno-
virus encompasses a deletion of a 48 to 60 aa region (from
701 to 739 nt in the Ad5 genome) in the CR1 region of
the E1A protein, which is responsible for p300 binding [12].
The Delta-24/39 adenovirus was constructed by gener-
ating a CR1 mutation similar to the one in Delta-39, on a
Delta-24 backbone [3] (Figure 1A). Adenoviral genome
deletions were verified through PCR amplification followed
by restriction enzyme digestion (Figure 1B), and then con-
firmed by sequencing (data not shown). As expected,
immunoprecipitation analyses of mutant E1A complexes
showed that CR1 mutant E1A proteins do not bind p300,
and that CR2 mutant proteins do not physically interact with
pRb (Figure 1C).
Delta-39 and Delta-24 Induced Comparable Oncolytic
Effects in Glioma Cells
We first studied the in vitro antiglioma activity of the
Delta-24, Delta-39, and Delta-24/39 adenoviruses in three
glioma cell lines: U-251 MG, D-54 MG, and U-87 MG. Crys-
tal violet assays showed that all three E1A mutant adeno-
viruses displayed antiglioma activity and that there was
no marked difference between the oncolytic effects of
Delta-24 and Delta-39 (Figure 2A). The antiglioma activity
of Delta-24/39 was inferior to the other two mutant adeno-
viruses (Figure 2A). A quantitative assessment of cell viabil-
ity by MTT demonstrated a consistent adenovirus-mediated
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cytopathic effect in U-251 MG glioma cells (Figure 2B). It
showed that the viral dose required to induce a 50% de-
crease in cell viability (IC50) was 0.5 MOI for Adwt, 1 MOI
for Delta-24 and Delta-39, and 4 MOI for Delta-24/39
(Figure 2B). As expected, the cytotoxicity of all three E1A
mutant adenoviruses was attenuated with respect to wild-
type adenovirus in NHA (Figure 2C). The IC50 was less than
4 MOI for Adwt and about 32 MOI for Delta-24. Impor-
tantly, with the maximum tested dose, more than 65% and
75% of the Delta-39– and Delta-24/39–infected cells, re-
spectively, were still viable (Figure 2C). We conclude that,
whereas the antiglioma efficiencies of Delta-24 and Delta-39
were similar, the double mutant E1A adenovirus, Delta-24/39,
produced a relatively attenuated anticancer effect. Addition-
ally, both CR1 mutant adenoviruses exhibited an attenuated
oncolytic profile, compared to Delta-24, in proliferating nor-
mal astrocytes.
Delta-39 Showed Broader Therapeutic Index than Delta-24
To determine whether the CPE was related to adenoviral
replication, we used a TCID50 assay. Delta-24 and Delta-39
replicated with a similar potency in glioma cells, whereas the
activity of Delta-24/39 was relatively attenuated (Figure 3A).
Notably, these experiments showed that the final titers of
Delta-39 and Delta-24/39 were slightly inferior to the initial
dose (5  104 pfu), highlighting the substantially diminished
ability of CR1 mutant adenoviruses to replicate in a dividing
NHA population (Figure 3A). In summary, Delta-24 and
Delta-24/39 replicated approximately 100 times better in
cancer cells than in normal cells, but Delta-39 replicated ap-
proximately 1000 times more efficiently in glioma cells than
in dividing NHA. Collectively, cell viability and viral replication
experiments indicate that Delta-39 exhibited an improved
therapeutic index when compared to Delta-24 or Delta-24/39.
We next asked whether Delta-39 triggered the cellular
DNA replication machinery differently in cancer versus nor-
mal cells. To stimulate adenoviral replication, E1A protein
binds pRb and releases E2F1 transcriptional activity [7].
Because E2F-1 can be autoactivated [11], E1A-mediated
release of E2F-1 transcriptional activation is an indicator
of the adenovirus’ ability to activate the DNA replication
machinery of the host cell. Hence, we directly analyzed the
E1A-mediated activation of an E2F-1 promoter coupled to a
luciferase gene. Cancer cells infected with any of the three
E1A mutant adenoviruses showed a similar E2F-1 promoter
activity, which was not significantly different from the activity
inmock-treated cells (P > 0.1, double-sided t-test) (Figure 3B),
underscoring the inefficient repression of Rb on E2F-1 in
these glioma cells [13]. However, when NHA were infected
with Delta-24, E2F-1 promoter activity was upregulated com-
pared to mock-treated cells (P < .01, double-sided t-test). In
contrast, infection with Delta-39 or Delta-24/39 did not sig-
nificantly modify E2F-1 promoter activity compared to con-
trol cultures (P > .1, double-sided t-test) (Figure 3B), which
is not surprising because the CR1 deletion in Delta-39
also weakens the binding of E1A to pRb and p107, in addi-
tion to abrogating the binding to p300 protein [12,14,15].
These results supported the replication assay findings, and
Figure 1. E1A mutant adenoviruses. (A) Schematic representation of the
E1A region of the genome of Adwt, and the E1A mutant adenoviruses
Delta-24, Delta-39, and Delta-24/39. The first nucleotide of the start codon
and third nucleotide of the stop codon of the E1A gene are indicated.
Shown are the 39-bp (gray box) and 24-bp (hatched box) deletions. For
clarity, the corresponding DNA segments of the CR1 and CR2 regions in
the E1A protein are also indicated. Restriction enzyme sites used to con-
firm E1A mutations are illustrated. (B) Identification of the deletions
through PCR amplification followed by restriction enzyme digestion. The
PCR product sizes and enzyme digestion profiles for the tested adeno-
viruses are as follows: Adwt, a 941-bp PCR fragment was digested into
three fragments (207, 322, and 412 bp) with BstXI and into two fragments
(315 and 626 bp) with XhoII; Delta-24, a 917-bp PCR fragment was
digested into two fragments (207 and 710 bp) with BstXI and two frag-
ments (315 and 602 bp) with XhoII; Delta-39, a 902-bp PCR product, di-
gested into three fragments (207, 283, and 412 bp) with BstXI; Delta-24/39,
a 878-bp PCR product, digested into two fragments (207 and 671 bp) with
BstXI. Note that the 39-bp deletion (701–739 nt) eliminated a XhoII restric-
tion site. Uncut PCR products are shown for size comparison. Samples
were analyzed on 1% agarose gel. M: 1-kb DNA ladder. (C) Disruption
of E1A–p300 or E1A–pRb interactions in CR1 or CR2 mutant adeno-
viruses. U-251 MG cells infected with Adwt, Delta-24, or Delta-24/39, or were
mock-infected. The cell lysates were immunoprecipitated with the anti-E1A
antibody. Precipitated proteins were separated by 10% SDS-PAGE and
immunoblotted for p300 and pRb. Input cell lysates (10% of total) were ana-
lyzed for E1A expression.
E1A Expression Level and Cancer Selectivity Jiang et al. 725
Neoplasia . Vol. 7, No. 8, 2005
Figure 2. In vitro antiglioma activity of the E1A mutant adenoviruses. (A) Adenoviral-mediated CPE was assayed by crystal violet staining. Glioma cells were
infected with Delta-24, Delta-39, or Delta-24/39 adenoviruses at the indicated doses. Experiments were completed when one of the adenovirus induced a CPE
of 80% or more at 10 MOI. Thus, the staining was performed in U-251 MG, D-54 MG, and U-87 MG cells at the fifth, fourth, and ninth days of the viral
infection, respectively. M, mock; UV, UV-inactivated adenovirus (10 MOI). (B and C) Cell viability was assessed by MTT analysis. U-251 MG (B) or NHA (C). Cells
were infected at the indicated MOI of Adwt, Delta-24, Delta-39, and Delta-24/39, or at the highest dose of UV-inactivated Adwt. Cell viability was assessed
6 days after infection. Data are mean ± SD of eight determinations, and are represented as cell viability relative to UV-inactivated adenovirus-treated cells (equal to
100%); UV, UV-inactivated adenovirus.
726 E1A Expression Level and Cancer Selectivity Jiang et al.
Neoplasia . Vol. 7, No. 8, 2005
suggested that Delta-39 and Delta-24 adenoviruses fun-
damentally differed in their abilities to trigger unscheduled
S-phase in normal cells.
Enhanced Proteasomal-Mediated Degradation Resulted
in Low Levels of CR1 Mutant E1A Protein
To examine how the CR1 deletion affects E1A protein
levels, we analyzed E1A protein expression in glioma cells
and NHA after infection with the E1A mutant adenoviruses.
Intriguingly, we found that the E1A protein was expressed at
markedly lower levels in U-251 MG and NHA treated with
Delta-39 or Delta-24/39 than in both Delta-24– infected
cultures. E1A protein expression in glioma cultures treated
with Delta-39 and Delta-24/39 was approximately 40%
and 75% lower, respectively, than in cultures treated with
Delta-24 (Figure 4A). In NHA cells infected with Delta-39 and
Delta-24/39, the level of expression of E1A protein was
similarly decreased (Figure 4A).
To determine whether the CR1 mutation affected the
stability of E1A protein, we monitored the temporal profile
of E1A protein degradation by infecting U-251 MG cells
with Adwt, CR1 mutant, or CR2 mutant adenoviruses and
by treating infected cells with the protein synthesis inhibi-
tor, anysomicin. Analyses of the E1A protein levels after
the addition of anisomycin showed that the stability of the
CR2 mutant E1A protein was similar to the wild-type E1A
protein (Figure 4B). However, the degradation of CR1 mu-
tant proteins was drastically accelerated (Figure 4B). As
expected, the stability of E1A protein was even more com-
promised in the double CR1–CR2 mutant E1A adenovirus
(Figure 4B). These results suggest that the 39-bp deletion in
the E1A CR1 region severely destabilizes the E1A protein.
Because E1A is a substrate for proteasomal-mediated deg-
radation [16], we were interested in ascertaining whether
proteosomal degradation was affecting mutant E1A levels.
To more precisely gauge the contribution of the protea-
some to CR1 mutant E1A degradation, U-251 MG cells
infected with Delta-24/39 were treated with the protea-
somal inhibitor, lactacystein. The CR1 mutant E1A species
were increased around eight-fold after prolonged lacta-
cystin treatment, whereas lactacystin treatment of cells
infected with Delta-24 or Adwt resulted in about two-fold
increase in E1A protein (Figure 4C). Collectively, these data
showed that the CR1 mutation produced a mutant form of
E1A protein whose stability was compromised by enhanced
proteasomal-mediated degradation.
Discussion
This is the first study to show that a mutation in the CR1 re-
gion of the E1A protein results in reduced protein stability and
alow level of E1A protein expression due to proteosomal-
mediated degradation. Importantly, a low level of E1A protein
does not significantly attenuate the capability of CR1 mutant
adenovirus to activate S-phase–associated genes and rep-
licate in glioma cells, but critically diminishes its activity in
normal astrocytes. These data indicate that the level of E1A
protein could be manipulated to construct mutant adeno-
viruses with replicative capacity restricted to cancer cells.
After our first report on the E1A mutant oncolytic Delta-24
adenovirus, it became one of the best characterized onco-
lytic adenoviruses to have been developed using functional
E1A deletions [3,17,18]. A modification of Delta-24, Delta-
24-RGD, enhanced the anticancer effect in glioma cells
in vitro and in vivo during preclinical characterization as-
sessments [4]. Current efforts are focused on improving the
therapeutic index of Delta-24 and its ability to utilize dereg-
ulated E2F activity to preferentially replicate in cancer cells
[3,19,20]. Previously, mutations in the CR1 region were
shown to abrogate or decrease the ability of E1A to interact
with p300/CBP, as well as Rb and Rb-related proteins [5].
Moreover, the CR1 and CR2 regions are apparently re-
quired to activate viral and cellular genes through indepen-
dent, redundant pathways, as only E1A mutants that fail
to bind to p300 and pRb simultaneously are completely
defective. Therefore, CR1 and CR2 mutations would be ex-
pected to weaken E1A-mediated disruption of the tightly
regulated cell cycle checkpoints to force normal cells into
S-phase. This tenet is supported by demonstrating improved
Figure 3. Replication potency of the E1A mutant adenoviruses in glioma
cells and proliferating normal astrocytes. (A) Viral replication profile in U-251
MG and NHA cells. The input dose was 1 MOI (5  104 pfu totally), and the
final titer of the new adenoviral progeny was quantified 3 days after the
infection using the TCID50 method. Viral titer is expressed as logarithmic
scale of plaque-forming units per milliliter. Shown are two independent
experiments for cancer and normal cells. (B) Modulation of the E2F-1
promoter activity in U-251 MG and NHA cells. After adenoviral infection,
U-251 MG and NHA cells were cotransfected with an E2F-1 promoter
reporter construct and the control vector, pRL-CMV. Then the cultures
were infected with the indicated viruses. Luciferase activity was defined
as firefly luciferase activity (reporter) normalized by renilla luciferase ac-
tivity (internal control), and expressed relative to the values obtained in
the Delta-24– treated U-251 MG cells (equal to 100%). Each experiment
was performed in triplicate. Data are shown as mean ± SD.
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replicative selectivity from a double CR1/CR2 mutant adeno-
virus over a CR2 mutant adenovirus in models with prolifer-
ating cells, such as organotypic keratinocyte cultures [23].
Our data are consistent with these observations and suggest
that the CR1 deletion is primarily responsible for the attenu-
ated replication pattern demonstrated by double CR1/CR2
mutant adenoviruses [23].
In addition to modification of the well-studied E1A inter-
actions with cell proteins [5], deletions in E1A protein may
have other effects. A novel finding in this study is that the CR1
deletion in the Delta-39 construct markedly reduces the
stability of E1A protein. Interestingly, this observation is con-
sistent with previous work reporting on the reduction of E1A
autoactivation of an E1A mutant with a similar CR1 deletion
[24]. Our data and previous data suggest that there is a
stoichiometric relationship between the level of expression
of E1A and its ability to modulate the activity of cellular and
adenoviral proteins. If this hypothesis were true, cancer cells
that already have impaired cell cycle checkpoint activity
would be permissive to the replication of E1A mutant adeno-
viruses expressing low E1A protein levels. Low levels of E1A
expression would, however, be disadvantageous in the set-
ting of multiple, extremely redundant, and overlapping mech-
anisms of cell cycle control in normal cells. Although it would
be difficult to pinpoint the exact contribution of a given level of
E1A expression to the selective replication of CR1 mutant
adenoviruses in cancer cells, the deletion in the Delta-39
construct apparently decreases E1A protein to a level lower
than the hypothetically required threshold needed to activate
DNA replication in normal cells. Our data showed that,
Figure 4. Expression and stability of E1A proteins. (A) Expression of E1A proteins in glioma cells and normal astrocytes. Immunoblotting analysis of the expression
of E1A protein in U-251 MG and NHA (left panel). Cells were collected 16 hours after being infected with the indicated viruses at 50 MOI. Proteins in the cell lysates
were separated by 10% SDS-PAGE and immunoblotted with anti-E1A and anti –-actin antibodies. The E1A signals were quantified by densitometry followed by
normalization to -actin levels (right panel). Data are represented as relative to E1A expression level displayed by Delta-24 in U-251 MG cells (equal to 100%). (B)
Stability of E1A proteins. U-251 MG cells were infected with the indicated adenoviruses and then treated with the protein synthesis inhibitor, anisomycin. Cell
lysates were collected at the indicated time points after anisomycin treatment, separated by 10% SDS-PAGE, and immunoblotted with the anti-E1A antibody (left
panel). Quantification of the E1A level was performed by densitometry analysis. Protein levels were represented as relative to E1A protein levels present at 0 hour
of the addition of anisomycin (equal to 100%). For clarity, data are presented as a linear regression graph (right panel). (C) Proteasomal-mediated degradation of
E1A. U-251 MG cells were infected with the indicated adenoviral constructs and then treated with lactacystein. Proteins were immunoblotted for E1A protein (left
panel). Protein levels were quantified by densitometry analysis. Shown are the ratios of E1A expressed by lactacystein-treated cultures versus untreated cultures
(right panel). L: lactacystin.
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together with disruptions in p300/CBP and pRb binding, a low
level of E1A could further detriment the ability of E1A to
properly inactivate cell cycle regulators in normal cells; none
of these two conditions, however, modified the ability of the
mutant adenovirus to replicate in cancer cells. Our results
indicate that further in vivo analyses need to be performed to
determine the impact of our mechanistic studies on the full
translation of Delta-39 to the clinical setting.
In summary, we report for the first time that a mutation in
the E1A gene results in low levels of E1A protein, condition-
ing the replication of the mutant adenoviruses specifically to
cancer cells. Thus, Delta-39 has the potential to be devel-
oped further into an efficacious antiglioma therapeutic tool.
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